Compare A O Smith Corp (AOS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
A O Smith Corp vs Viatris Inc — how do they compare? A O Smith Corp trades at $59.46 (market cap $8.33B), while Viatris Inc trades at $16.27 (market cap $18.94B). The key difference: Viatris Inc is far larger — about 2.3× A O Smith Corp's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| AOS | VTRS | |
|---|---|---|
Market Cap | $8.33B | $18.94B |
Sector | Industrials | Health |
52-Week High | $80.47 | $17.39 |
52-Week Low | $55.78 | $8.74 |
Enterprise Value | $8.78B | $31.15B |
Dividend Yield | 2.35% | 2.95% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About A O Smith Corp
A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells primarily to Asian countries and operates sales offices to expand distribution and market its product portfolio.
Read more on AOS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
